• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

具有不同群组数量的成本效益分析中差异贴现的实际意义。

Practical implications of differential discounting in cost-effectiveness analyses with varying numbers of cohorts.

机构信息

Department of Public Health, Erasmus University Medical Centre, Rotterdam, The Netherlands.

出版信息

Value Health. 2011 Jun;14(4):438-42. doi: 10.1016/j.jval.2010.09.009. Epub 2011 May 19.

DOI:10.1016/j.jval.2010.09.009
PMID:21669368
Abstract

OBJECTIVE

To call attention to the influence of the number of birth-cohorts used in cost-effectiveness analysis (CEA) models on incremental cost-effectiveness ratios (ICERs) under differential discounting.

METHODS

The consequences of increasing the number of birth-cohorts are demonstrated using a CEA of cervical cancer prevention as an example. The cost-effectiveness of vaccinating 12-year-old girls against the human papillomavirus is estimated with the MISCAN microsimulation screening analysis model for 1, 10, 20, and 30 birth-cohorts. Costs and health effects are discounted with equal rates of 4% and alternatively with differential rates of 4% and 1.5% respectively. The effects of increasing the number of cohorts are shown by comparing the ICERs under equal and differential discounting.

RESULTS

The ICER decreases as the number of cohorts increases under differential discounting, but not under equal discounting.

CONCLUSIONS

The variation of ICERs with the number of cohorts under differential discounting prompts questions regarding the appropriate specification of CEA models and interpretation of their results. In particular, it raises concerns that arbitrary variation in study specification leads to arbitrary variation in results. Such variations could lead to erroneous policy decisions. These findings are relevant to CEA guidance authorities, CEA practitioners, and decision makers. Our results do not imply a problem with differential discounting per se, yet they highlight the need for practical guidance for its use.

摘要

目的

提醒人们注意在差异化贴现下,成本效益分析(CEA)模型中使用的出生队列数量对增量成本效益比(ICER)的影响。

方法

以宫颈癌预防的 CEA 为例,展示了增加出生队列数量的后果。使用 MISCAN 微观模拟筛查分析模型,针对 1、10、20 和 30 个出生队列,估计了对 12 岁女孩接种人乳头瘤病毒疫苗的成本效益。成本和健康效果以相等的 4%贴现率或分别以 4%和 1.5%的差异化贴现率贴现。通过比较差异化贴现和均等贴现下的 ICER 来显示增加队列数量的效果。

结果

在差异化贴现下,随着队列数量的增加,ICER 会降低,但在均等贴现下则不会。

结论

差异化贴现下 ICER 随队列数量的变化引发了对 CEA 模型适当规范和结果解释的问题。特别是,它引起了人们对研究规范的任意变化会导致结果的任意变化的担忧。这种变化可能导致错误的政策决策。这些发现与 CEA 指导机构、CEA 从业者和决策者有关。我们的结果并不意味着差异化贴现本身存在问题,但它们强调了需要对其使用提供实际指导。

相似文献

1
Practical implications of differential discounting in cost-effectiveness analyses with varying numbers of cohorts.具有不同群组数量的成本效益分析中差异贴现的实际意义。
Value Health. 2011 Jun;14(4):438-42. doi: 10.1016/j.jval.2010.09.009. Epub 2011 May 19.
2
Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.荷兰人乳头瘤病毒疫苗接种的成本效益分析
J Natl Cancer Inst. 2009 Aug 5;101(15):1083-92. doi: 10.1093/jnci/djp183. Epub 2009 Jul 1.
3
Mathematical models of cervical cancer prevention in the Asia Pacific region.亚太地区宫颈癌预防的数学模型
Vaccine. 2008 Aug 19;26 Suppl 12:M17-29. doi: 10.1016/j.vaccine.2008.06.018.
4
Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia.斯洛文尼亚 HPV 疫苗接种与宫颈癌筛查计划的成本效益分析。
Eur J Public Health. 2010 Aug;20(4):415-21. doi: 10.1093/eurpub/ckp208. Epub 2010 Jul 12.
5
Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands.预防性接种人乳头瘤病毒16/18型疫苗预防宫颈癌的成本效益:将现有队列模型应用于荷兰的情况
Vaccine. 2009 Jul 30;27(35):4776-83. doi: 10.1016/j.vaccine.2009.05.085. Epub 2009 Jun 17.
6
Mathematical models of cervical cancer prevention in Latin America and the Caribbean.拉丁美洲和加勒比地区宫颈癌预防的数学模型
Vaccine. 2008 Aug 19;26 Suppl 11:L59-72. doi: 10.1016/j.vaccine.2008.05.063.
7
Health and economic impact associated with a quadrivalent HPV vaccine in Italy.意大利四价人乳头瘤病毒疫苗的健康和经济影响
Gynecol Oncol. 2009 Feb;112(2):370-6. doi: 10.1016/j.ygyno.2008.09.031. Epub 2008 Nov 28.
8
Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening.比利时人乳头瘤病毒疫苗接种的成本效益:不要忘记宫颈癌筛查。
Int J Technol Assess Health Care. 2009 Apr;25(2):161-70. doi: 10.1017/S0266462309090217.
9
The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients.宫颈癌筛查和人乳头瘤病毒疫苗接种对肾移植受者的健康及经济影响
Transplantation. 2009 Apr 15;87(7):1078-91. doi: 10.1097/TP.0b013e31819d32eb.
10
The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa.在南非的宫颈癌筛查项目中添加人乳头瘤病毒疫苗的潜在成本效益。
Vaccine. 2009 Oct 19;27(44):6196-202. doi: 10.1016/j.vaccine.2009.08.004. Epub 2009 Aug 19.

引用本文的文献

1
Economic analyses in cardiac electrophysiology: from clinical efficacy to cost utility.心脏电生理学中的经济分析:从临床疗效到成本效用。
Europace. 2024 Feb 1;26(2). doi: 10.1093/europace/euae031.
2
A comprehensive review of official discount rates in guidelines of health economic evaluations over time: the trends and roots.一篇关于卫生经济评价指南中官方贴现率的全面综述:趋势和根源。
Eur J Health Econ. 2022 Dec;23(9):1577-1590. doi: 10.1007/s10198-022-01445-x. Epub 2022 Mar 2.
3
Adherence to Discounting Guidelines: Evidence from Over 2000 Published Cost-Effectiveness Analyses.
遵守折扣准则:来自 2000 多项已发表成本效益分析的证据。
Pharmacoeconomics. 2020 Aug;38(8):809-818. doi: 10.1007/s40273-020-00916-4.
4
Economic evaluation of meningococcal vaccines: considerations for the future.脑膜炎球菌疫苗的经济学评价:未来的考虑因素。
Eur J Health Econ. 2020 Mar;21(2):297-309. doi: 10.1007/s10198-019-01129-z. Epub 2019 Nov 21.
5
Discounting in Economic Evaluations.经济性评价中的折扣
Pharmacoeconomics. 2018 Jul;36(7):745-758. doi: 10.1007/s40273-018-0672-z.
6
Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community.疫苗健康经济评估方法与免疫决策框架:欧洲疫苗经济学共同体的共识框架
Pharmacoeconomics. 2016 Mar;34(3):227-44. doi: 10.1007/s40273-015-0335-2.
7
Dealing with Time in Health Economic Evaluation: Methodological Issues and Recommendations for Practice.健康经济评估中的时间处理:方法学问题与实践建议
Pharmacoeconomics. 2015 Dec;33(12):1255-68. doi: 10.1007/s40273-015-0309-4.
8
Multicohort models in cost-effectiveness analysis: why aggregating estimates over multiple cohorts can hide useful information.多队列模型在成本效益分析中的应用:为何汇总多个队列的估计值可能会隐藏有用信息。
Med Decis Making. 2013 Apr;33(3):407-14. doi: 10.1177/0272989X12453503. Epub 2012 Aug 27.